Shionogi & Co. will acquire global rights to edaravone, an FDA‑approved therapy for amyotrophic lateral sclerosis (marketed as Radicava ORS and I.V. Radicava in the U.S.), under a $2.5 billion agreement with Tanabe Pharma. The transaction transfers marketed products and revenue streams to Shionogi and creates a new entity to house both oral and I.V. formulations. The move immediately adds a revenue‑generating rare‑disease asset to Shionogi’s portfolio and expands its global neurology footprint. Financial terms reportedly include the headline $2.5 billion consideration and will accelerate Shionogi’s presence in ALS treatments.